Want to see SRRK full AI Analyst Report?
SRRK Stock Chart & Stats
$47.67
-$1.81(-3.66%)
At close: 4:00 PM EDT
$47.67
-$1.81(-3.66%)
Day’s Range― - ―
52-Week Range$27.07 - $58.49
Previous Close$47.67
Volume838.71K
Average Volume (3M)1.53M
Market Cap
$6.66B
Enterprise Value$6.90K
Total Cash (Recent Filing)$492.09M
Total Debt (Recent Filing)$203.83M
Price to Earnings (P/E)―
Beta1.63
Next Earnings
Nov 18, 2026EPS Estimate
-0.85Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.31
Shares Outstanding121,785,280
10 Day Avg. Volume1,038,028
30 Day Avg. Volume1,529,778
Financial Highlights & Ratios
PEG Ratio-0.40
Price to Book (P/B)20.58
Price to Sales (P/S)0.00
P/FCF Ratio-16.81
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$62.10Price Target Upside30.27% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)-3.27
Revenue Forecast (FY)$6.00M
Bulls Say, Bears Say
Bulls Say
Regulatory MilestoneBLA acceptance with a fixed PDUFA date provides a near-term regulatory inflection that materially de-risks development-stage uncertainty. A defined review timeline enables concrete commercial planning, partner negotiations and capital decisions tied to a potential approval outcome over the next months.
Manufacturing RedundancyHaving two independent fill/finish paths reduces single-site failure risk and supports supply continuity if one facility faces inspection or capacity issues. This durable operational redundancy strengthens launch reliability, regulatory resilience and long-term commercialization scalability versus single-source supply.
Liquidity & Financing OptionalityA sizeable cash balance plus ATM proceeds, a debt facility draw option and plans to monetize a priority review voucher provide multiple financing levers. This structural liquidity and optionality supports launch investments, clinical programs and working capital needs without immediate reliance on dilutive events.
Bears Say
No Commercial RevenueThe company remains pre-revenue with materially widening net losses and sustained negative operating cash flow. Persistent burn without product sales makes the business structurally dependent on external financing, increasing dilution and refinancing risk if commercialization timing slips or payer uptake is slower than expected.
Rising LeverageDebt has increased sharply over recent periods, pushing leverage to about 0.75x versus equity. Higher indebtedness reduces financial flexibility, raises refinancing and covenant risk, and can limit capacity for opportunistic R&D or commercial investment if cash burn persists or revenue ramps are delayed.
Manufacturing/Regulatory Timing RiskA pending FDA inspection classification for Catalent Indiana creates structural regulatory timing uncertainty that could delay approval or complicate EMA timing. Reliance on third-party manufacturing and unresolved inspection outcomes heighten execution risk for supply, market entry and sustained commercialization planning.
Scholar Rock Holding News
SRRK FAQ
What was Scholar Rock Holding’s price range in the past 12 months?
Scholar Rock Holding lowest stock price was $27.07 and its highest was $58.49 in the past 12 months.
What is Scholar Rock Holding’s market cap?
Scholar Rock Holding’s market cap is $6.66B.
When is Scholar Rock Holding’s upcoming earnings report date?
Scholar Rock Holding’s upcoming earnings report date is Nov 18, 2026 which is in 90 days.
How were Scholar Rock Holding’s earnings last quarter?
Scholar Rock Holding released its earnings results on Aug 06, 2026. The company reported -$0.84 earnings per share for the quarter, beating the consensus estimate of -$0.841 by $0.001.
Is Scholar Rock Holding overvalued?
According to Wall Street analysts Scholar Rock Holding’s price is currently Undervalued.
Does Scholar Rock Holding pay dividends?
Scholar Rock Holding does not currently pay dividends.
What is Scholar Rock Holding’s EPS estimate?
Scholar Rock Holding’s EPS estimate is -0.85.
How many shares outstanding does Scholar Rock Holding have?
Scholar Rock Holding has 121,785,280 shares outstanding.
What happened to Scholar Rock Holding’s price movement after its last earnings report?
Scholar Rock Holding reported an EPS of -$0.84 in its last earnings report, beating expectations of -$0.841. Following the earnings report the stock price went up 9.964%.
Which hedge fund is a major shareholder of Scholar Rock Holding?
Currently, no hedge funds are holding shares in SRRK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Scholar Rock Holding Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$62.10 (30.27% Upside)
$62.10 (30.27% Upside)
Blogger Sentiment
Bullish
SRRK Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 183.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.2%
Last 30 Days ▲ 7.1%
Last 30 Days ▲ 7.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
25.62%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
53.96%
Trailing 12-Months
Company Description
Scholar Rock Holding
Scholar Rock Holding Corporation is a biopharmaceutical firm dedicated to discovering and advancing treatments for severe medical conditions by targeting the crucial role of protein growth factor signaling. Their lead therapeutic candidate, Apitegromab, an agent designed to inhibit the activation of latent myostatin, has successfully concluded Phase 3 clinical trials for spinal muscular atrophy (SMA). Another key program, SRK-181, is currently undergoing Phase 1 clinical assessment for tackling cancers that exhibit resistance to established checkpoint inhibitor treatments, including anti-PD-1 or anti-PD-L1 antibody therapies. Beyond these, the company cultivates a robust pipeline of innovative potential therapies, aiming to significantly improve the lives of individuals grappling with various severe ailments, such as neurological muscle conditions, malignancies, and fibrotic disorders. In a strategic partnership, Scholar Rock is collaborating with Gilead Sciences, Inc. to identify and develop targeted inhibitors of transforming growth factor beta (TGF-beta) activation, specifically for addressing fibrotic diseases. Established in 2012, Scholar Rock Holding Corporation operates from its headquarters in Cambridge, Massachusetts.
SRRK Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong forward momentum: the BLA is accepted with a fixed PDUFA date, management has established two independent manufacturing paths (reducing single-site risk), commercial operations are launch-ready, the pipeline is advancing (Phase II OPAL recruitment, FORGE initiated, SRK-439 dosing), and the company finished the quarter with a healthy cash balance and financing optionality. Main negatives are the outstanding FDA inspection classification for Catalent Indiana (which also affects EMA timing), ongoing third-party manufacturing/regulatory timing risk, and expected payer/reimbursement friction that could delay patient access after approval. On balance, the positive regulatory progress, commercial preparedness, clinical achievements and solid cash position outweigh the operational and reimbursement risks discussed on the call.View all SRRK earnings summariesSRRK Stock 12 Month Forecast
Average Price Target
$62.10
▲(30.27% Upside)
Technical Analysis
Ultragenyx Pharmaceutical
―
Viking Therapeutics
―
Xenon
―
Immunovant
―
NewAmsterdam Pharma Company
―
Ownership Overview
20.30% Insiders
29.59% Mutual Funds
14.12% Other Institutional Investors
23.81% Public Companies and
Individual Investors